No Data
Increased revenue without increased profits, junshi bio (01877) faces many hidden concerns behind its growth.
In the third quarter, junshi bio increased revenue without increasing profits, reducing research and development expenses to cut losses. However, shareholders faced market scrutiny for reducing their holdings when a new drug was approved.
junshi bio - U (688180): Bright commercial performance, significant year-on-year and quarter-on-quarter reduction in losses on the profit side.
Junshi Bio released the third quarter report of 2024. In the first three quarters of 2024, the company achieved revenue of 1.271 billion yuan, an increase of 28.87% year-on-year, with a net loss attributable to the parent of -0.927 billion yuan, a decrease of 34.12% year-on-year, net of non-recurring gains and losses.
HK stocks unusual movement: junshi bio (01877) is currently down by over 4%, with a net loss of 0.927 billion yuan in the first three quarters. Shareholders have recently collectively reduced their shareholding by over 1%.
junshi bio (01877) is now down more than 4%, as of the time of publication, down 4.2%, at 13.24 Hong Kong dollars, with a turnover of 11.964 million Hong Kong dollars.
Announcement Highlights | In the first three quarters, PetroChina's net profit exceeded 130 billion yuan; The People's Insurance's net profit increased by 77.2% year-on-year in the first nine months of this year.
PetroChina's net profit in the first three quarters exceeded 130 billion yuan, how is the growth rate? The People's Insurance's profit in the year-on-year period increased by nearly 80%, how large is the scale?
junshi bio announced that Shanghai Tianying and its concerted action person collectively reduced their shareholding in the company by more than 1%.
Junshi Bio (01877) announced that from August 24, 2023 to October 8, 2024, LVC Renaissance Fund, LVC Fund I, and LVC Fund II reduced their H-share holdings due to fund term and liquidity arrangements, totaling approximately 8.241 million H shares. On September 25, 2024, the company disclosed the "Announcement of Shanghai Junshi Biomedical Technology Co., Ltd.'s Major Shareholder's Shareholding Reduction Plan" (Announcement No.: Pro.)
junshi bio (01877.HK) narrowed its losses in the first three quarters to 0.927 billion RMB.
Junshi Bio (01877.HK) announced the financial results for the first three quarters ending in September, achieving revenue of 1.271 billion RMB in accordance with China accounting standards, an annual increase of 28.9%. The loss narrowed from 1.407 billion yuan in the same period last year to 0.927 billion yuan, with a loss per share of 94 cents.
No Data
No Data